46 related articles for article (PubMed ID: 29291383)
1. Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC.
Martins VL; Caley MP; Moore K; Szentpetery Z; Marsh ST; Murrell DF; Kim MH; Avari M; McGrath JA; Cerio R; Kivisaari A; Kähäri VM; Hodivala-Dilke K; Brennan CH; Chen M; Marshall JF; O'Toole EA
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476432
[TBL] [Abstract][Full Text] [Related]
2. [Cutaneous squamous cell carcinomas in EBDR: how can they be detected?].
Boudan R; Bourrat E; Galadari A
Soins; 2023 Nov; 68(880):33-35. PubMed ID: 37931995
[TBL] [Abstract][Full Text] [Related]
3. [Cutaneous squamous cell carcinomas: a complication of severe forms of hereditary epidermolysis bullosa].
Bourrat E
Soins; 2023 Nov; 68(880):36-38. PubMed ID: 37931996
[TBL] [Abstract][Full Text] [Related]
4. Why are squamous cancers so aggressive in recessive dystrophic epidermolysis bullosa? Can we find new therapeutic approaches?
O'Shaughnessy RFL
Br J Dermatol; 2023 Dec; 190(1):7-8. PubMed ID: 37831585
[No Abstract] [Full Text] [Related]
5. Whole-Exome Sequencing Validates a Preclinical Mouse Model for the Prevention and Treatment of Cutaneous Squamous Cell Carcinoma.
Knatko EV; Praslicka B; Higgins M; Evans A; Purdie KJ; Harwood CA; Proby CM; Ooi A; Dinkova-Kostova AT
Cancer Prev Res (Phila); 2017 Jan; 10(1):67-75. PubMed ID: 27923803
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic Plasticity of Cutaneous Squamous Cell Carcinoma Mediated by Cyclooxygenase-2.
Moon H; Kim D; Donahue LR; White AC
J Invest Dermatol; 2020 Aug; 140(8):1665-1669.e5. PubMed ID: 31981577
[No Abstract] [Full Text] [Related]
7. Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa.
Nyström A; Bornert O; Kühl T; Gretzmeier C; Thriene K; Dengjel J; Pfister-Wartha A; Kiritsi D; Bruckner-Tuderman L
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E705-E714. PubMed ID: 29305555
[TBL] [Abstract][Full Text] [Related]
8. Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases.
Hwang A; Kwon A; Miller CH; Reimer-Taschenbrecker A; Paller AS
Orphanet J Rare Dis; 2024 May; 19(1):206. PubMed ID: 38769503
[TBL] [Abstract][Full Text] [Related]
9. Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives.
Condorelli AG; Dellambra E; Logli E; Zambruno G; Castiglia D
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739489
[TBL] [Abstract][Full Text] [Related]
10. Recessive dystrophic epidermolysis bullosa-associated squamous-cell carcinoma: an enigmatic entity with complex pathogenesis.
Rodeck U; Uitto J
J Invest Dermatol; 2007 Oct; 127(10):2295-6. PubMed ID: 17853916
[TBL] [Abstract][Full Text] [Related]
11. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
Kim M; Murrell DF
Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
[TBL] [Abstract][Full Text] [Related]
12. Genetic Profiles of Squamous Cell Carcinomas Associated with Recessive Dystrophic Epidermolysis Bullosa Unveil NOTCH and TP53 Mutations and an Increased MYC Expression.
Sans-DeSanNicolas L; Caratú G; Vidal-Cortés O; Sanchez-Redondo S; Ferrer B; Mancuso F; González-Sanchez E; Pérez-Alea M; McGrail K; Hernandez-Losa J; Bodet D; Vivancos A; Garcia-Patos V; Recio JA
J Invest Dermatol; 2018 Jun; 138(6):1423-1427. PubMed ID: 29291383
[No Abstract] [Full Text] [Related]
13. Understanding the pathogenesis of recessive dystrophic epidermolysis bullosa squamous cell carcinoma.
South AP; O'Toole EA
Dermatol Clin; 2010 Jan; 28(1):171-8. PubMed ID: 19945632
[TBL] [Abstract][Full Text] [Related]
14. A recurrent nonsense mutation occurring as a de novo event in a patient with recessive dystrophic epidermolysis bullosa.
Cuadrado-Corrales N; Sánchez-Jimeno C; García M; Ayuso C; De Lucas R; Vicario JL; Conti CJ; Zambruno G; Escamez MJ; Del Rio M
Dermatology; 2011; 223(3):219-21. PubMed ID: 21849769
[No Abstract] [Full Text] [Related]
15. Targeting the Jak/Signal Transducer and Activator of Transcription 3 Pathway with Ruxolitinib in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa-Squamous Cell Carcinoma.
Jacków J; Rami A; Hayashi R; Hansen C; Guo Z; DeLorenzo D; Pappalardo A; Alvarez Cespedes D; Kim AL; Perez-Lorenzo R; Owens DM; Christiano AM
J Invest Dermatol; 2021 Apr; 141(4):942-946. PubMed ID: 33069729
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
